Franchi A, Cragoe E, Pouysségur J
J Biol Chem. 1986 Nov 5;261(31):14614-20.
A new method based on the toxicity of low intracellular pH (pHi) was developed to isolate fibroblast variants overexpressing Na+/H+ antiport activity. Chinese hamster lung fibroblasts (CCL39) were incubated for 60 min in medium containing 50 mM NH4Cl. Removal of external NH+4 induced a rapid and lethal intracellular acidification when the Na+/H+ antiporter was inhibited during the 60 min of the pHi recovery phase. The inhibition was provoked either by adding 5-(N-methyl,N-propyl)amiloride (MPA, LD50 = 0.3 microM) or by reducing external [Na+] (LD50 = 25 mM). Progressively increasing the MPA concentration during the acid-load selection led to the isolation of two stable variants: AR40 and AR300, resistant, respectively, to 40 and 300 microM MPA. In response to an acid-load, these variants display a much higher rate of pHi recovery due to an overexpression of Na+/H+ antiport activity. In addition, AR40 and AR300 have an altered Na+/H+ antiporter: in AR300 cells K0.5 of MPA for inhibiting Na+/H+ exchange is shifted from 5 X 10(-8) to 1.5 X 10(-6) M, Km (Na+) is decreased 2-fold, and Vmax is increased 4.5-fold. Alternatively reducing Na+ concentration of the pHi recovery saline medium in a stepwise manner led to the selection of another class of variants (DD8 and DD12) also characterized by an altered Na+/H+ antiporter and an increased expression level. The 10-fold increased rate of amiloride-sensitive Na+ influx of DD12 is accounted for by a 4-fold increase in Vmax and a 2.5-fold increase in affinity for Na+ or Li+ at the external site. Interestingly, the affinity for the amiloride analog MPA and for external H+ is unchanged in DD12. In conclusion, the genetic approach presented here: provides a general and specific method for selecting variants of the Na+/H+ antiporter with increased expression levels and/or with structural alterations and demonstrates that the external Na+- and amiloride-binding sites are not identical, since they can be genetically altered independently of each other.
基于低细胞内pH值(pHi)毒性开发了一种新方法,用于分离过表达Na+/H+逆向转运活性的成纤维细胞变体。将中国仓鼠肺成纤维细胞(CCL39)在含有50 mM氯化铵的培养基中孵育60分钟。当在pHi恢复阶段的60分钟内Na+/H+逆向转运体被抑制时,去除细胞外NH4+会导致快速且致命的细胞内酸化。通过添加5-(N-甲基,N-丙基)氨氯吡咪(MPA,半数致死剂量LD50 = 0.3 microM)或降低细胞外[Na+](LD50 = 25 mM)来引发抑制。在酸负荷选择过程中逐渐增加MPA浓度,导致分离出两种稳定变体:AR40和AR300,它们分别对40和300 microM MPA具有抗性。响应酸负荷时,由于Na+/H+逆向转运活性的过表达,这些变体显示出更高的pHi恢复速率。此外,AR40和AR300的Na+/H+逆向转运体发生了改变:在AR300细胞中,抑制Na+/H+交换的MPA的半最大抑制浓度(K0.5)从5×10^(-8) M 转变为1.5×10^(-6) M,米氏常数(Km)(Na+)降低了2倍,最大反应速度(Vmax)增加了4.5倍。或者,逐步降低pHi恢复盐溶液培养基中的Na+浓度,导致选择另一类变体(DD8和DD12),其特征同样是Na+/H+逆向转运体发生改变且表达水平增加。DD12中氨氯吡咪敏感的Na+内流速率增加了10倍,这是由于最大反应速度增加了4倍以及对外位点处Na+或Li+的亲和力增加了2.5倍。有趣的是,DD12中对氨氯吡咪类似物MPA和对外源H+的亲和力没有变化。总之,本文提出的遗传方法:提供了一种通用且特异的方法,用于选择Na+/H+逆向转运体表达水平增加和/或结构改变的变体,并证明细胞外Na+结合位点和氨氯吡咪结合位点并不相同,因为它们可以彼此独立地发生遗传改变。